Am Fam Physician. 2000 Feb 15;61(4):1178-1180.
Coronary heart disease (CHD) is the cause of death in approximately two thirds of patients with type 2 diabetes. Recent evidence suggests that complications associated with CHD can be reduced through intensified treatment of hypertension and dyslipidemia. The Scandinavian Simvastatin Survival Study (4S) has previously shown that treatment with simvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, reduced mortality from CHD by 42 percent. The 4S study was a double-blind, randomized, prospective, placebo-controlled, multicenter trial of simvastatin therapy in patients with CHD carried out in 94 clinical centers throughout Scandinavia. Herman and associates performed an analysis of the 4S data comparing outcomes in three subgroups: patients with normal fasting glucose levels, patients with impaired fasting glucose tolerance and patients with clinical diabetes.
Over the five years of observation, treatment with simvastatin reduced cardiovascular disease-related hospitalizations by 23 percent in patients with normal fasting glucose levels, by 30 percent in patients with impaired glucose tolerance and by 40 percent in patients with diabetes. Simvastatin therapy reduced the average cost of cardiovascular disease-related hospitalizations by $3,585 in patients with normal fasting glucose levels (this offset 60 percent of the cost of the simvastatin therapy), and by $4,478 in patients with impaired glucose tolerance (this offset 74 percent of the cost of simvastatin therapy). Patients with diabetes had a net cost savings of $1,801 each.
The authors conclude that simvastatin significantly reduced cardiovascular disease-related hospitalizations in all three of these groups. In addition, the benefits of aggressive lipid lowering therapy were greatest in patients with diabetes.
Herman WH, et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care. November 1999;22:1771–8.
editor's note: This study supports previous research on the value of lipid control in patients with diabetes. Aggressive control of lipids, despite the high up-front costs, is likely to reduce the impact of common macrovascular complications such as ischemic heart disease. Clinicians should work aggressively to achieve the lipid goals set by the American Diabetes Association (i.e., a low-density lipoprotein level of less than 100 mg per dL [2.59 mmol per L]).—j.n.
Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions